Which of the following opioids undergoes minimal hepatic metabolism and is preferred in patients with severe liver disease?

Explanation

## Opioid Metabolism and Hepatic Clearance **Key Point:** Among the listed opioids, morphine is the **relatively safest** choice in severe liver disease. Although morphine undergoes glucuronidation, it is predominantly renally cleared (~90% as morphine and its glucuronide conjugates), making it less dependent on hepatic function compared to fentanyl, codeine, and methadone. ### Opioid Metabolism Pathways | Opioid | Primary Metabolism | Hepatic Dependence | Use in Liver Disease | | --- | --- | --- | --- | | **Morphine** | Glucuronidation (UGT enzymes); ~90% renal excretion | **Low** | **Relatively preferred** | | **Fentanyl** | Extensive CYP3A4 hepatic metabolism | High (~75%) | Caution; accumulation risk | | **Codeine** | Extensive CYP2D6 hepatic metabolism | High (~80%) | Avoid; active metabolite accumulation | | **Methadone** | Extensive CYP3A4/CYP2D6 hepatic metabolism | High (~90%) | Avoid; prolonged half-life, accumulation | **High-Yield:** Morphine's glucuronidation pathway (via UGT1A3/UGT2B7) is relatively preserved even in moderate hepatic impairment, and the bulk of drug and metabolites are renally excreted. This pharmacokinetic profile makes morphine the **comparatively safer** opioid in cirrhosis and hepatic failure among the options listed (KD Tripathi, Essentials of Medical Pharmacology, 8th ed.). **Clinical Pearl:** Morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G) are active metabolites that accumulate in **renal failure** (not hepatic failure), causing hyperalgesia, neurotoxicity (M3G), and enhanced analgesia/respiratory depression (M6G). In **hepatic failure**, the concern is reduced glucuronidation capacity and potential accumulation of morphine itself — but this risk is far less than the extensive CYP-dependent hepatic metabolism seen with fentanyl, codeine, and methadone. **Warning:** Fentanyl, codeine, and methadone are extensively metabolized by hepatic CYP enzymes. In liver disease, their bioavailability increases and clearance decreases markedly, leading to drug accumulation and serious toxicity. These agents should be avoided or used with extreme caution in severe hepatic impairment. **Mnemonic:** **Morphine = Mostly Renal** — its predominant renal excretion pathway makes it the safest opioid choice in hepatic dysfunction among the commonly tested options.